Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Paul Jank is a leading translational researcher in gynecologic oncology, with a primary focus on homologous recombination deficiency (HRD) as a critical biomarker in ovarian cancer. His most cited work, a 2022 study in a real-world cohort of 514 ovarian carcinoma samples, demonstrated the diagnostic utility of next-generation sequencing to evaluate HRD status—including BRCA1/BRCA2 mutations and over 26,000 single-nucleotide polymorphisms. This research has been instrumental in refining targeted therapy strategies, directly impacting clinical decision-making for patients with advanced ovarian cancer. With 40 citations to this landmark paper, Dr. Jank’s contributions are shaping precision oncology by bridging genomic profiling and personalized treatment. His work underscores the importance of HRD testing in routine practice, offering a pathway to more effective, tailored interventions. Dr. Jank’s dedication to translating complex genomic data into actionable clinical insights makes him a vital voice in the fight against ovarian cancer, inspiring both clinicians and researchers to advance biomarker-driven care.